First National Bank of Omaha Boosts Position in Novartis AG (NVS)
First National Bank of Omaha increased its position in shares of Novartis AG (NYSE:NVS) by 0.8% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 100,464 shares of the company’s stock after acquiring an additional 774 shares during the period. First National Bank of Omaha’s holdings in Novartis were worth $8,435,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also recently bought and sold shares of NVS. Parnassus Investments CA lifted its stake in Novartis by 18.5% during the 3rd quarter. Parnassus Investments CA now owns 9,447,817 shares of the company’s stock worth $811,095,000 after acquiring an additional 1,477,168 shares in the last quarter. Lord Abbett & CO. LLC acquired a new position in Novartis during the 2nd quarter worth about $29,576,000. Boston Partners lifted its stake in Novartis by 14.9% during the 3rd quarter. Boston Partners now owns 1,857,435 shares of the company’s stock worth $159,461,000 after acquiring an additional 240,573 shares in the last quarter. Schafer Cullen Capital Management Inc. lifted its stake in Novartis by 9.2% during the 2nd quarter. Schafer Cullen Capital Management Inc. now owns 2,780,606 shares of the company’s stock worth $232,097,000 after acquiring an additional 233,292 shares in the last quarter. Finally, Amundi Pioneer Asset Management Inc. lifted its stake in Novartis by 228.8% during the 3rd quarter. Amundi Pioneer Asset Management Inc. now owns 317,300 shares of the company’s stock worth $27,240,000 after acquiring an additional 220,800 shares in the last quarter. 11.09% of the stock is currently owned by hedge funds and other institutional investors.
Shares of Novartis AG (NYSE NVS) opened at $86.23 on Wednesday. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.21 and a quick ratio of 0.91. The stock has a market capitalization of $196,589.80, a PE ratio of 17.56, a price-to-earnings-growth ratio of 1.97 and a beta of 0.73. Novartis AG has a 12-month low of $72.67 and a 12-month high of $94.19.
Several research firms recently issued reports on NVS. JPMorgan Chase & Co. reissued a “neutral” rating on shares of Novartis in a research note on Thursday, January 18th. Barclays lowered Novartis from an “equal weight” rating to an “underweight” rating in a research note on Wednesday, October 25th. UBS Group reissued a “neutral” rating on shares of Novartis in a research note on Monday, January 15th. Zacks Investment Research lowered Novartis from a “hold” rating to a “sell” rating in a research note on Tuesday, January 2nd. Finally, Bank of America lowered Novartis from a “neutral” rating to an “underperform” rating in a research note on Wednesday, December 6th. Five research analysts have rated the stock with a sell rating, eight have issued a hold rating and three have issued a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus price target of $85.32.
Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company’s segments include Innovative Medicines, Sandoz, Alcon and Corporate activities.
Want to see what other hedge funds are holding NVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novartis AG (NYSE:NVS).
Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.